[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Norwegian University of Science and Technology\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":511},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,43,0,25,[9,47,77,105,134,159,184,199,214,229,244,274,302,318,333,348,363,378,393,408,423,440,455,470,485],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100652726","time-restricted-eating-and-high-intensity-interval-training-after-gestational-diabetes-100652726",false,"NCT07776886","Time-restricted Eating and High-intensity Interval Training After Gestational Diabetes","Time-restricted Eating and High-intensity Interval Training After Gestational Diabetes (TRE-HIIT Moms)","TRE-HIITmoms","Inclusion Criteria:\n\n* Gestational diabetes mellitus in most recent pregnancy\n* Within 6-12 weeks postpartum\n* Understands oral and written Norwegian or English\n* Able to walk or run on a treadmill or ride a bike for at least 60 minutes\n* Living in the Trondheim area\n\nExclusion Criteria:\n\n* Pregnant or trying to become pregnant\n* Diagnosed with type 1 or type 2 diabetes\n* Diagnosed with cardiovascular disease\n* Have a history of eating disorders (anorexia, bulimia, or binge eating disorder)\n* Habitual eating window of less than 12 hours\u002Fday\n* Engaging in regular high-intensity endurance training (once per week or more)\n* Intention of starting an exercise programme and\u002For a dietary strategy within the study period\n* Shift work that includes night shifts\n* Bariatric surgery\n* Any other reason which, according to the researchers, makes the potential participant ineligible","FEMALE","18 Years","50 Years",{"count":22,"type":23},56,"ESTIMATED","INTERVENTIONAL",[26],"NA","This trial will recruit participants who had gestational diabetes in their most previous pregnancy. Participants will be randomly allocated into two groups: one intervention group and one control group 6-12 weeks after giving birth. The intervention group will undergo an 8-week supervised intervention consisting of time-restricted eating and endurance exercise training with moderate-to-high intensity. The investigators will assess cardiorespiratory fitness, body composition, and other markers of cardiovascular and metabolic health before and after the 8 weeks. Additionally, the participants in the intervention group will be encouraged to continue exercising and eating time restricted after the supervised period and follow them up by telephone until one year from the baseline visit. The investigators will measure the same outcomes at the follow-up as on the previous two test points.",[29],"Gestational Diabetes Mellitus With Baby Delivered",[31,32,33],"Exercise","Time-restricted eating","High-intensity interval training","NOT_YET_RECRUITING","2026-08-17",{"date":37,"type":38},"2026-08-20","ACTUAL",{"date":40,"type":23},"2026-08-15",{"date":42,"type":23},"2029-01",{"name":44,"class":45},"Norwegian University of Science and Technology","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":55,"minAge":19,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":24,"phases":59,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":46},"100564348","digital-follow-up-of-aerobic-interval-training-in-outpatients-with-mental-disorders-100564348","NCT06628011","Digital Follow-up of Aerobic Interval Training in Outpatients With Mental Disorders","Digital Follow-up of Exercise Training in Outpatients With Mental Disorders","DIG-EX","Inclusion Criteria:\n\n* Individuals receiving outpatient mental health treatment at the clinics of mental health at St. Olavs Hospital,.\n\n  .-18-65 years old\n* Both men and women able to carry out exercise training.\n* Participants must be capable of giving informed consent and use HelsaMi.\n\nExclusion Criteria:\n\n* Contraindications for exercise training and testing according to the ACSM specifications; life-threatening or terminal medical conditions; unable to carry out intervention or test procedures; pregnancy; mothers \\<6 months post-partum.\n* Inpatients at an acute psychiatric ward or have any planned surgery that would interfere with the intervention.","ALL","65 Years",{"count":58,"type":23},40,[26],"This randomized-controlled trial (RCT) will investigate if digital follow-up of exercise, i.e. followup through the new citizen portal HelsaMi, coupled with an exercise app can result in exercise adherence and improved oxygen uptake in individuals with mental disorders (MD). Secondary, the project will provide information regarding effects on cardiovascular disease risk-factors, functional capacity, quality of life, satisfaction, and cost through a randomized-controlled trial (RCT) including individuals with MDs.\n\nOutcomes assessed in this project, such as maximal oxygen uptake, functional capacity, and quality of life, are strongly related to the ability to carry out activities of daily living. These outcomes are associated with benefits such as reduced sick leave, extended life expectancy, independence, and improved health status with increasing age. Economically, with the world population growing older and health care resources being stretched, there is clearly a need to apply and evaluate effective alternative methods to improve somatic health on a broader scale in a sustainable fashion, preferably utilizing existing platforms and exercise apps.",[62],"Severe Mental Disorder",[64,65,66,67,68],"Peak oxygen uptake","Aerobic high-intensity interval training","Digital follow-up","Mental health disorder","Exercise physiology","RECRUITING","2026-08-14",{"date":35,"type":38},{"date":73,"type":38},"2025-01-01",{"date":75,"type":23},"2030-09-01",{"name":44,"class":45},{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":55,"minAge":86,"maxAge":4,"enrollmentInfo":87,"targetDuration":89,"studyType":90,"phases":4,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":46},"100602025","memory-deterioration-in-alzheimer-disease-100602025","NCT07118137","Memory Deterioration in Alzheimer Disease","Translational Neuroscience CAG for Alzheimer's Disease","MemAD","Inclusion Criteria:\n\n* Confirmed diagnosis based on current ICD criteria for AD or MCI .\n* \\>55years.\n* Norwegian native speaker\n* Lives at home and not in a health institution\n\nExclusion Criteria:\n\n* Patients with severe cognitive impairment that prevents assessment with the selected modalities (planned cut-off: CDR \\> 2).\n* Presence of brain tumors.\n* History of traumatic brain injury.\n* History of cranial surgery.\n* Contraindications to the selected imaging modalities (e.g., 7T MRI or EEG).\n* Diagnosis of other neurodegenerative diseases such as Parkinson's disease or ALS.\n\n  7T MRI contraindications:\n* Large tattoos close to the head region, permanent makeup or unremoveable piercings\n* Certain models of pacemakers (if pacemaker implantet, MRI physicist at 7T-lab will be conferred)\n* Implantet metal in body (clips, stents, prothesis, skrews, plates, teeth etc.)",true,"55 Years",{"count":88,"type":23},30,"1 Year","OBSERVATIONAL","Semantic AD",[93,94,95,96],"Alzheimer Disease","Neurodegenerative Diseases","Magnetic Resonance Imaging","Memory Impairment","2026-08-12",{"date":99,"type":38},"2026-08-13",{"date":101,"type":38},"2023-10-15",{"date":103,"type":23},"2027-12-31",{"name":44,"class":45},{"id":106,"slug":107,"hasResults":12,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":85,"sex":55,"minAge":56,"maxAge":4,"enrollmentInfo":113,"targetDuration":115,"studyType":90,"phases":4,"briefSummary":116,"conditions":117,"keywords":122,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":128,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":46},"100550540","multimodal-assesment-of-alzheimer-patients-100550540","NCT06448403","Multimodal Assesment of Alzheimer Patients","Multimodal Assessment of Cognitive Impairment in Alzheimer Patients","MultiAD","Inclusion Criteria:\n\n* MCI and AD according to relevant ICD-criterias.\n* Control cohort is age and gender matched with other cohorts.\n\nExclusion Criteria:\n\n* Uneligibility for any of the planned neuroimagery devices (MRI, EEG)\n* AD diagnosis before the age of 65 (Early-onset AD).\n* Brain tumor\n* Traumtic head injury\n* Earlier neurosurgery\n* Other neyrodegenerative diseases (i.e Parkinson and ALS)\n* Diseases related to inflammation and auto-immunity (i.e MS)",{"count":114,"type":23},60,"5 Years","The goal of this study is to learn more about the changes in the brains of patients with cognitive impairment (MCI) and Alzheimer's Disease (AD).\n\nThe main questions the study aims to answer are:\n\n1. What findings can be used to earlier detect patients that will develop Alzheimers?\n2. Which differences are seen between healthy and cognitively impaired patients?\n3. Which differences are seen between patients with Alzheimers disease?\n\nParticipants will undergo:\n\n* Cognitive tests\n* Magnetic resonance imaging (MRI)\n* Electroencephalography (EEG)\n* Blood sample collection\n* Fecal sample collection\n* A randomized group will undergo polysomnography analysis.",[118,119,120,121],"Mild Cognitive Impairment","Alzheimer Disease, Late Onset","Cognitive Impairment","Dementia",[123,124,125,126,94,121,127],"Alzheimer Disease (AD)","Mild cognitive impairment (MCI)","Brain Diseases","Nervous System Disorders","Cognitive impairment",{"date":99,"type":38},{"date":130,"type":38},"2024-07-01",{"date":132,"type":23},"2030-12-29",{"name":44,"class":45},{"id":135,"slug":136,"hasResults":12,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":12,"sex":55,"minAge":19,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":24,"phases":144,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":153,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":46},"100539937","trust-ace---anticancer-treatment-cardiotoxicity-identification-by-echocardiography-100539937","NCT06310330","TRUST-ACE - Anticancer-treatment Cardiotoxicity Identification by Echocardiography","Technology Revising Ultrasound Solutions for Tomorrow - Anticancer-treatment Cardiotoxicity Identification by Echocardiography","TRUST-ACE","Inclusion Criteria:\n\n* Breast cancer and referral for follow-up to identify potential CTRCD\n\nExclusion Criteria:\n\n* Not willing or able to consent",{"count":143,"type":23},250,[26],"TRUST-ACE will compare a simplified echocardiographic protocol focusing on ventricular function with the guideline recommended comprehensive echocardiographic examination using a randomised design in follow-up of breast-cancer patients with respect to identification of cancer treatment related cardiac dysfunction (CTRCD).\n\nSecondly, the study will evaluate whether novel tools used to improve standardization of recordings as well as automated measurements of central measurements, e.g. ejection fraction (EF) and global longitudinal strain (GLS) can improve the precision of echocardiography in daily clinical practice.",[147],"Breast Neoplasm Malignant Primary",[149,150,151,152],"echocardiography","breast cancer","artificial intelligence","cardiotoxicity",{"date":99,"type":38},{"date":155,"type":38},"2024-03-08",{"date":157,"type":23},"2026-12-31",{"name":44,"class":45},{"id":160,"slug":161,"hasResults":12,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":55,"minAge":19,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":169,"conditions":170,"keywords":172,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":178,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":46},"100327083","bariatric-surgery-and-pharmacokinetics-of-paracetamol-100327083","NCT03538457","Bariatric Surgery and Pharmacokinetics of Paracetamol","Bariatric Surgery and Pharmacokinetics of Paracetamol: BAR-MEDS Paracetamol","Inclusion Criteria:\n\n* Preparing to undergo gastric bypass or sleeve gastrectomy in Central Norway\n* Being a Norwegian citizen\n\nExclusion Criteria:\n\n* Having previously undergone resections in the GI-tract","70 Years",{"count":168,"type":23},12,"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on paracetamol are investigated.",[171],"Obesity, Morbid",[173,174,175,176,177],"Bariatric surgery","Gastrointestinal tract","Biological availability","Pharmacokinetics","Acetaminophen",{"date":99,"type":38},{"date":180,"type":38},"2016-11-02",{"date":182,"type":23},"2026-10",{"name":44,"class":45},{"id":185,"slug":186,"hasResults":12,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":55,"minAge":19,"maxAge":166,"enrollmentInfo":190,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":191,"conditions":192,"keywords":193,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":195,"startDateStruct":196,"completionDateStruct":197,"leadSponsor":198,"locationsCount":46},"100326846","bariatric-surgery-and-pharmacokinetics-of-valsartan-100326846","NCT03535376","Bariatric Surgery and Pharmacokinetics of Valsartan","Bariatric Surgery and Pharmacokinetics of Valsartan: BAR-MEDS Valsartan",{"count":168,"type":23},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on valsartan are investigated.",[171],[173,174,175,176,194],"Valsartan",{"date":99,"type":38},{"date":180,"type":38},{"date":182,"type":23},{"name":44,"class":45},{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":55,"minAge":19,"maxAge":166,"enrollmentInfo":205,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":206,"conditions":207,"keywords":208,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":210,"startDateStruct":211,"completionDateStruct":212,"leadSponsor":213,"locationsCount":46},"100325660","bariatric-surgery-and-pharmacokinetics-of-metoprolol-100325660","NCT03519906","Bariatric Surgery and Pharmacokinetics of Metoprolol","Bariatric Surgery and Pharmacokinetics of Metoprolol: BAR-MEDS Metoprolol",{"count":168,"type":23},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on metoprolol are investigated.",[171],[173,174,175,176,209],"Metoprolol",{"date":99,"type":38},{"date":180,"type":38},{"date":182,"type":23},{"name":44,"class":45},{"id":215,"slug":216,"hasResults":12,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":55,"minAge":19,"maxAge":166,"enrollmentInfo":220,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":221,"conditions":222,"keywords":223,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":225,"startDateStruct":226,"completionDateStruct":227,"leadSponsor":228,"locationsCount":46},"100325659","bariatric-surgery-and-pharmacokinetics-of-losartan-100325659","NCT03519893","Bariatric Surgery and Pharmacokinetics of Losartan","Bariatric Surgery and Pharmacokinetics of Losartan: BAR-MEDS Losartan",{"count":168,"type":23},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on losartan are investigated.",[171],[173,174,175,176,224],"Losartan",{"date":99,"type":38},{"date":180,"type":38},{"date":182,"type":23},{"name":44,"class":45},{"id":230,"slug":231,"hasResults":12,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":55,"minAge":19,"maxAge":166,"enrollmentInfo":235,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":236,"conditions":237,"keywords":238,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":240,"startDateStruct":241,"completionDateStruct":242,"leadSponsor":243,"locationsCount":46},"100323913","bariatric-surgery-and-pharmacokinetics-of-lamotrigine-100323913","NCT03497143","Bariatric Surgery and Pharmacokinetics of Lamotrigine","Bariatric Surgery and Pharmacokinetics Lamotrigine: BAR-MEDS Lamotrigine",{"count":168,"type":23},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on lamotrigine are investigated.",[171],[173,174,175,176,239],"Lamotrigine",{"date":99,"type":38},{"date":180,"type":38},{"date":182,"type":23},{"name":44,"class":45},{"id":245,"slug":246,"hasResults":12,"nctId":247,"briefTitle":248,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":12,"sex":55,"minAge":251,"maxAge":252,"enrollmentInfo":253,"targetDuration":4,"studyType":24,"phases":255,"briefSummary":256,"conditions":257,"keywords":260,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":46},"100595560","smartwork---a-decision-support-system-to-promote-return-to-work-among-people-sick-listed-with-musculoskeletal-disorders-100595560","NCT07034040","SmaRTWork - a Decision Support System to Promote Return to Work Among People Sick-listed With Musculoskeletal Disorders","SmaRTWork","Inclusion Criteria:\n\n* Individuals 20-59 years old (working age)\n* Living in Norway\n* Own a smart phone with internet access\n* Sick-listed due to a musculoskeletal disorder for up to 12 weeks\n* The main diagnosis for sick leave is back pain, neck pain or widespread pain. For example one of the following (ICPC-2 diagnoses codes): Neck symptom\u002Fcomplaint (L01), Back symptom\u002Fcomplaint (L02), Low back symptom\u002Fcomplaint (L03), Muscle pain (L18), Back syndrome without radiating pain (L84)\n\nExclusion Criteria:\n\n* Pregnant\n* No employer (unemployed or self-employed)\n* Poor Norwegian comprehension\n* Sick listed for more than 3 months the previous 12 months\n* Have a planned date for RTW during the next week\n* previous participation in the trial or concurrent participation in another study that could interfere with the current trial\n* Unable to take part in exercise\u002Fphysical activity (e.g., use of walking aids, unable to get up and down on the floor independently)\n* Leg pain worse than back pain\n* Red flags that could indicate serious underlying pathology:\n\n  * Changes in bladder or bowel function\n  * General feeling of being unwell (malaise), fever and\u002For unexplained weight loss\n  * Reduced muscle (motor) function, sensory loss, walking problems or balance problems\n  * Neck or back pain that started after the age of 55 or feel different from previous pain episodes\n  * Pain that does not improve with rest or light activity or pain that is much worse during the night\n  * Previous or ongoing cancer\n  * Use of steroids\u002Fimmune suppressing medications or drug use\n  * Pain that is trauma (injury) related\n* Serious ongoing somatic (e.g., unstable heart disease) or mental disorder (e.g., psychosis, ongoing manic episode, suicidal ideation)\n* Pain has not been assessed by a clinician","20 Years","59 Years",{"count":254,"type":23},298,[26],"The objective of this study is to evaluate the effect of an intervention, SmaRTWork, on return to work compared to usual care for individuals who are sick-listed due to musculoskeletal disorders. Potential participants are individuals of working age (20-59 years) sick-listed due to a musculoskeletal disorder (neck pain, low back pain, or widespread pain) for up to 12 weeks living in Norway. The primary outcome will be time to sustainable return to work. We will also evaluate the effect on other work outcomes and health outcomes. We will also interview participants and stakeholders about their experience with the intervention.",[258,259],"Sick Leave","Musculoskeletal",[261,262,263,264,265],"Sick leave","musculoskeletal disorder","sickness absence","return to work","mHealth","2026-07-10",{"date":268,"type":38},"2026-07-13",{"date":270,"type":23},"2026-08",{"date":272,"type":23},"2028-12",{"name":44,"class":45},{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":278,"acronym":279,"eligibilityCriteria":280,"healthyVolunteers":85,"sex":55,"minAge":19,"maxAge":281,"enrollmentInfo":282,"targetDuration":283,"studyType":90,"phases":4,"briefSummary":284,"conditions":285,"keywords":290,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":46},"100505681","predisposing-factors-for-post-stroke-epilepsy-100505681","NCT05864547","Predisposing Factors for Post-stroke Epilepsy","PRESTEP","Inclusion Criteria:\n\n* First time stroke patients with capacity to consent, admitted to the stroke unit at St. Olavs hospital.\n* Modified Rankin Scale (mRS) ≤ 2 before the stroke\n\nExclusion Criteria:\n\n* Previous stroke or brain surgery\n* Traumatic brain injuries\n* Neurodegenerative diseases\n* Brain tumors\n* Epilepsy before the stroke\n* Hydrocephalus\n* Aphasia\n* Serious psychiatric disorders\n* MRI incompatibility and claustrophobia","85 Years",{"count":88,"type":23},"6 Months","The goal of this observational study is to learn about epilepsy after a stroke (post-stroke epilepsy). The main questions it aims to answer are:\n\n* What make some patients develop epilepsy after a stroke?\n* Does sleep have an impact on the development of post-stroke epilepsy?\n\nParticipants will undergo:\n\n* Electroencephalography (EEG)\n* Magnetic resonance imaging (MRI)\n* Polysomnography (only patients)\n\nBlood tests will also be taken. The patient group will be compared to the healthy controls. Researchers will also look into medical records of stroke patients hospitalized at St. Olavs hospital and collect relevant information.",[286,287,288,289],"Post Stroke Epilepsy","Stroke","Epilepsy","Seizures",[291,125,292,126,293],"Cerebrovascular Disorders","Central Nervous System Diseases","Vascular Diseases","2026-07-06",{"date":296,"type":38},"2026-07-07",{"date":298,"type":38},"2023-05-08",{"date":300,"type":23},"2030-12",{"name":44,"class":45},{"id":303,"slug":304,"hasResults":12,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":55,"minAge":19,"maxAge":166,"enrollmentInfo":308,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":309,"conditions":310,"keywords":311,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":316,"leadSponsor":317,"locationsCount":46},"100323914","bariatric-surgery-and-pharmacokinetics-of-lercanidipine-100323914","NCT03497156","Bariatric Surgery and Pharmacokinetics of Lercanidipine","Bariatric Surgery and Pharmacokinetics Lercanidipine: BAR-MEDS Lercanidipine",{"count":168,"type":23},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on lercanidipine are investigated.",[171],[173,174,175,176,312],"Lercanidipine",{"date":314,"type":38},"2026-07-08",{"date":180,"type":38},{"date":182,"type":23},{"name":44,"class":45},{"id":319,"slug":320,"hasResults":12,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":55,"minAge":19,"maxAge":166,"enrollmentInfo":324,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":325,"conditions":326,"keywords":327,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":329,"startDateStruct":330,"completionDateStruct":331,"leadSponsor":332,"locationsCount":46},"100322338","bariatric-surgery-and-pharmacokinetics-of-irbesartan-100322338","NCT03476603","Bariatric Surgery and Pharmacokinetics of Irbesartan","Bariatric Surgery and Pharmacokinetics Irbesartan: BAR-MEDS Irbesartan",{"count":168,"type":23},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on irbesartan are investigated.",[171],[173,174,175,176,328],"Irbesartan",{"date":314,"type":38},{"date":180,"type":38},{"date":182,"type":23},{"name":44,"class":45},{"id":334,"slug":335,"hasResults":12,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":55,"minAge":19,"maxAge":166,"enrollmentInfo":339,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":340,"conditions":341,"keywords":342,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":344,"startDateStruct":345,"completionDateStruct":346,"leadSponsor":347,"locationsCount":46},"100322336","bariatric-surgery-and-pharmacokinetics-of-ibuprofen-100322336","NCT03476577","Bariatric Surgery and Pharmacokinetics of Ibuprofen","Bariatric Surgery and Pharmacokinetics Ibuprofen: BAR-MEDS Ibuprofen",{"count":168,"type":23},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on ibuprofen are investigated.",[171],[173,174,175,176,343],"Ibuprofen",{"date":314,"type":38},{"date":180,"type":38},{"date":182,"type":23},{"name":44,"class":45},{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":55,"minAge":19,"maxAge":166,"enrollmentInfo":354,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":355,"conditions":356,"keywords":357,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":359,"startDateStruct":360,"completionDateStruct":361,"leadSponsor":362,"locationsCount":46},"100322334","bariatric-surgery-and-pharmacokinetics-of-hydrochlorothiazide-100322334","NCT03476551","Bariatric Surgery and Pharmacokinetics of Hydrochlorothiazide","Bariatric Surgery and Pharmacokinetics Hydrochlorothiazide: BAR-MEDS Hydrochlorothiazide",{"count":168,"type":23},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on hydrochlorothiazide are investigated.",[171],[173,174,175,176,358],"Hydrochlorothiazide",{"date":314,"type":38},{"date":180,"type":38},{"date":182,"type":23},{"name":44,"class":45},{"id":364,"slug":365,"hasResults":12,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":55,"minAge":19,"maxAge":166,"enrollmentInfo":369,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":370,"conditions":371,"keywords":372,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":374,"startDateStruct":375,"completionDateStruct":376,"leadSponsor":377,"locationsCount":46},"100322333","bariatric-surgery-and-pharmacokinetics-of-gabapentin-100322333","NCT03476538","Bariatric Surgery and Pharmacokinetics of Gabapentin","Bariatric Surgery and Pharmacokinetics Gabapentin: BAR-MEDS Gabapentin",{"count":168,"type":23},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on gabapentin are investigated.",[171],[173,174,175,176,373],"Gabapentin",{"date":314,"type":38},{"date":180,"type":38},{"date":182,"type":23},{"name":44,"class":45},{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":55,"minAge":19,"maxAge":166,"enrollmentInfo":384,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":385,"conditions":386,"keywords":387,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":389,"startDateStruct":390,"completionDateStruct":391,"leadSponsor":392,"locationsCount":46},"100322332","bariatric-surgery-and-pharmacokinetics-of-fluoxetine-100322332","NCT03476525","Bariatric Surgery and Pharmacokinetics of Fluoxetine","Bariatric Surgery and Pharmacokinetics Fluoxetine: BAR-MEDS Fluoxetine",{"count":168,"type":23},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on fluoxetine are investigated.",[171],[173,174,175,176,388],"Fluoxetine",{"date":314,"type":38},{"date":180,"type":38},{"date":182,"type":23},{"name":44,"class":45},{"id":394,"slug":395,"hasResults":12,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":55,"minAge":19,"maxAge":166,"enrollmentInfo":399,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":400,"conditions":401,"keywords":402,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":404,"startDateStruct":405,"completionDateStruct":406,"leadSponsor":407,"locationsCount":46},"100321094","bariatric-surgery-and-pharmacokinetics-of-enalapril-100321094","NCT03460366","Bariatric Surgery and Pharmacokinetics of Enalapril","Bariatric Surgery and Pharmacokinetics Enalapril: BAR-MEDS Enalapril",{"count":168,"type":23},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on enalapril are investigated.",[171],[173,174,175,176,403],"Enalapril",{"date":314,"type":38},{"date":180,"type":38},{"date":182,"type":23},{"name":44,"class":45},{"id":409,"slug":410,"hasResults":12,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":55,"minAge":19,"maxAge":166,"enrollmentInfo":414,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":415,"conditions":416,"keywords":417,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":419,"startDateStruct":420,"completionDateStruct":421,"leadSponsor":422,"locationsCount":46},"100321091","bariatric-surgery-and-pharmacokinetics-of-candesartan-100321091","NCT03460327","Bariatric Surgery and Pharmacokinetics of Candesartan","Bariatric Surgery and Pharmacokinetics Candesartan: BAR-MEDS Candesartan",{"count":168,"type":23},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on candesartan are investigated.",[171],[173,174,175,176,418],"Candesartan",{"date":314,"type":38},{"date":180,"type":38},{"date":182,"type":23},{"name":44,"class":45},{"id":424,"slug":425,"hasResults":12,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":55,"minAge":19,"maxAge":166,"enrollmentInfo":429,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":430,"conditions":431,"keywords":432,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":434,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":46},"100320259","bariatric-surgery-and-pharmacokinetics-of-chlorprothixene-100320259","NCT03449485","Bariatric Surgery and Pharmacokinetics of Chlorprothixene","Bariatric Surgery and Pharmacokinetics of Chlorprothixene: BAR-MEDS Chlorprothixene",{"count":168,"type":23},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study we investigate the pharmacokinetic effects of bariatric surgery on chlorprothixene.",[171],[173,174,175,176,433],"Chlorprothixene",{"date":314,"type":38},{"date":436,"type":38},"2018-01-02",{"date":438,"type":23},"2026-12",{"name":44,"class":45},{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":55,"minAge":19,"maxAge":166,"enrollmentInfo":446,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":447,"conditions":448,"keywords":449,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":451,"startDateStruct":452,"completionDateStruct":453,"leadSponsor":454,"locationsCount":46},"100320258","bariatric-surgery-and-pharmacokinetics-of-quetiapine-100320258","NCT03449472","Bariatric Surgery and Pharmacokinetics of Quetiapine","Bariatric Surgery and Pharmacokinetics Quetiapine: BAR-MEDS Quetiapine",{"count":168,"type":23},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on quetiapine are investigated.",[171],[173,174,175,176,450],"Quetiapine fumarate",{"date":314,"type":38},{"date":436,"type":38},{"date":182,"type":23},{"name":44,"class":45},{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":55,"minAge":19,"maxAge":166,"enrollmentInfo":461,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":462,"conditions":463,"keywords":464,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":466,"startDateStruct":467,"completionDateStruct":468,"leadSponsor":469,"locationsCount":46},"100320205","bariatric-surgery-and-pharmacokinetics-of-apixaban-100320205","NCT03448783","Bariatric Surgery and Pharmacokinetics of Apixaban","Bariatric Surgery and Pharmacokinetics of Apixaban: BAR-MEDS Apixaban",{"count":168,"type":23},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study we investigate the pharmacokinetic effects of bariatric surgery on apixaban.",[171],[173,174,175,176,465],"Apixaban",{"date":314,"type":38},{"date":436,"type":38},{"date":438,"type":23},{"name":44,"class":45},{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":55,"minAge":19,"maxAge":166,"enrollmentInfo":476,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":477,"conditions":478,"keywords":479,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":481,"startDateStruct":482,"completionDateStruct":483,"leadSponsor":484,"locationsCount":46},"100319547","bariatric-surgery-and-pharmacokinetics-of-ramipril-100319547","NCT03440177","Bariatric Surgery and Pharmacokinetics of Ramipril","Bariatric Surgery and Pharmacokinetics of Ramipril: BAR-MEDS Ramipril",{"count":168,"type":23},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study we investigate the pharmacokinetic effects of bariatric surgery on ramipril.",[171],[173,174,175,176,480],"Ramipril",{"date":314,"type":38},{"date":436,"type":38},{"date":438,"type":23},{"name":44,"class":45},{"id":486,"slug":487,"hasResults":12,"nctId":488,"briefTitle":489,"officialTitle":489,"acronym":490,"eligibilityCriteria":491,"healthyVolunteers":12,"sex":55,"minAge":19,"maxAge":4,"enrollmentInfo":492,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":494,"conditions":495,"keywords":497,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":509,"locationsCount":510},"100409483","the-eminence-study---petmr-imaging-of-head-neck-cancer-100409483","NCT04612075","The EMINENCE Study - PET\u002FMR Imaging of Head Neck Cancer","EMINENCE","Inclusion Criteria:\n\n* willing and able to give full written consent according to the protocol approved by the Regional Ethics Committee\n* histologically confirmed squamous cell carcinoma in the head neck region (pharynx, larynx, oral cavity or sinonasal area)\n* locally advanced disease without sign of dissemination (T3\u002FT4 and\u002For N1-3, M0) on diagnostic imaging\n* scheduled for definitive radiotherapy with curative intent with or without concomitant chemotherapy\n* adequate renal function: Creatinine clearance ≥ 60 ml\u002Fminute\n* lymph node metastasis from cancer of unknown primary of the upper neck (i.e. level II-III) were PET\u002FCT is negative outside the head-neck region can be considered for inclusion at the discretion of the study investigators.\n\nExclusion Criteria:\n\n* general contraindications for MRI (pacemaker, aneurysm clips, any form of metal in the body, severe claustrophobia)\n* serious comorbidity (including previous or othe cancer) that in the opinion of the investigator would compromise the patient's ability to complete the study of interfere with the evaluation of the study objectives (e.g. poorly controlled diabetes mellitus)\n* histologically confirmed SCC of same or other origin within the last five years\n* patient wants to withdraw for any reason during the study",{"count":493,"type":23},390,"Head and neck cancers (HNC) often receive radiotherapy as part of their treatment. However, unacceptable failure rates and severe side effects remain a challenge. The improvements in radiotherapy are closely related to improvements in medical imaging. Functional imaging, where intratumoural characteristics such as tumour oxygenation, metabolism, and blood vessel function can be quantified, offers possibilities to personalize the radiotherapy. In this study we will establish the clinical workflow for PET- and MRI-based radiotherapy in HNC by acquiring images prior to and during radiotherapy to develop new concepts for image-based biologically adaptive radiotherapy, both based on photon-based radiotherapy and also proton therapy, which soon will be available for cancer patients in Norway. The investigators aim to contribute towards further developments of personalised high-precision radiotherapy for HNC patients resulting in improved outcome, reduced side-effects and better quality of life.",[496],"Head and Neck Neoplasms",[498,499,500,501,502],"Diagnostic Imaging","Functional Imaging","Nuclear magnetic Resonance Imaging","Positron-Emission Tomography","Radiotherapy","2026-04-09",{"date":505,"type":38},"2026-04-14",{"date":507,"type":38},"2021-01-12",{"date":272,"type":23},{"name":44,"class":45},2,""]